What is Mycoplasma pneumoniae – IgG? Mycoplasma pneumoniae is a type of bacteria that commonly causes respiratory infections, especially atypical pneumonia—a milder, slower-developing form of pneumonia often referred to as "walking pneumonia." It is also associated with sore throat, prolonged cough, sinusitis, and bronchitis. In some cases, it can contribute to more serious complications such as asthma exacerbations, ear infections, or skin rashes. The IgG antibody test detects long-term immune response to Mycoplasma pneumoniae. IgG antibodies typically appear several weeks after infection and may remain in the bloodstream for months or even years, indicating past exposure or infection.
Mycoplasma Pneumoniae Antibody (IgG) testing plays a pivotal role in the serological diagnosis of infections caused by the bacterium Mycoplasma pneumoniae, a common agent of atypical pneumonia and other respiratory tract infections. This antibody is a specific type of immunoglobulin G (IgG), which the human immune system produces in response to an infection with this organism. The presence and levels of Mycoplasma pneumoniae IgG antibodies in a patient's blood are measured to determine whether they have been exposed to the pathogen, either in the recent past or as a more distant infection. Typically, the body starts producing these antibodies 1-2 weeks after the initial infection, and their levels peak around 4-6 weeks post-infection. The detection of IgG antibodies is crucial because it indicates a past or ongoing immune response against Mycoplasma pneumoniae. However, it's important to note that the presence of IgG antibodies alone cannot definitively confirm an active infection, as they can persist in the bloodstream for months or even years after the initial exposure, indicating immunity from past infection. Therefore, the interpretation of Mycoplasma pneumoniae IgG tests often involves considering the patient's clinical presentation, symptoms, and, if available, comparing antibody titers from acute and convalescent phases of the illness. This comparison can help to ascertain whether the detected antibodies are from a recent infection or a past exposure. In some cases, the testing for IgM antibodies, which are produced earlier in the infection, might be conducted alongside IgG testing for a more comprehensive understanding of the infection's timeline. Mycoplasma pneumoniae IgG antibody testing is a valuable tool in the epidemiological tracking and management of respiratory infections, particularly in outbreak settings or when diagnosing atypical pneumonia cases.
helpful to identify acute infections caused by Mycoplasma pneumoniae
The "Mycoplasma pneumoniae IgA" test is a specific blood test designed to detect the presence of Immunoglobulin A (IgA) antibodies against Mycoplasma pneumoniae, a bacterium that causes respiratory infections, most notably a form of pneumonia often referred to as "walking pneumonia." Unlike typical pneumonia, walking pneumonia caused by Mycoplasma pneumoniae is generally milder and can sometimes manifest with symptoms so slight that individuals might not even realize they are ill, hence the name "walking." The body produces IgA antibodies as part of its immune response to a Mycoplasma pneumoniae infection. These antibodies are a type of protein that the immune system uses to help fight off infections, specifically at mucosal sites such as the lungs and throat in this case. When a person is infected with Mycoplasma pneumoniae, their immune system starts to produce antibodies to fight the infection, including IgA antibodies. By measuring the levels of IgA antibodies in the blood, healthcare providers can determine if a recent or ongoing infection with Mycoplasma pneumoniae is present. It's important to note, however, that the presence of IgA antibodies alone may not definitively diagnose an active infection, as these antibodies can remain in the body for some time after the infection has resolved. Therefore, this test is often used in conjunction with other tests, including those for different types of antibodies, like IgM and IgG, to get a comprehensive understanding of the infection's timeline and status. The Mycoplasma pneumoniae IgA test is particularly useful in diagnosing infections in individuals who present with symptoms of a respiratory infection but where common causes have been ruled out. Symptoms of a Mycoplasma pneumoniae infection can include a persistent cough, fever, sore throat, and fatigue. Identifying the specific cause of the symptoms can help healthcare providers recommend the most effective treatment, which may include antibiotics specifically effective against Mycoplasma bacteria. Understanding the role of IgA in fighting this infection also provides insights into the body's immune response and helps in managing and monitoring the infection's progression or resolution.
a small bacterium transmitted via organism-containing droplets
To detect an active or recent mycoplasma (type of bacteria) infection
genus of bacteria that lack a cell wall
Myelin is the protective sheath surrounding nerves
MYELIN BASIC PROTEIN (MBP) Function: Myelin is the protective sheath surrounding nerves. Myelin basic protein (MBP) is believed to be important in the process of myelination, the building of myelin sheaths. Thus, MBP is often a target in the demyelination process in various neuroimmune disorders. Antibodies Appear in: - Multiple sclerosis - Autism - PANDAS / ANDAS / OCD - Lupus - Toxin exposure Known Cross-Reactions: - Chlamydia pneumoniae, - Herpes-6 - streptococcal protein - gliadin - Acinetobacter - Mycobacterium avium - IgG and IgM to tissue-bound-Bisphenol A (BPA) Clinical Significance: MBP antibodies are detected in various neuroimmune disorders including multiple sclerosis. Consequently, antibodies to MBP are accepted markers of inflammation in various neuroimmune disorders. In possible cases of multiple sclerosis (MS) the measurement of antibodies against MBP may predict early conversion to clinically definite MS; in a study by Berger et al patients who were seropositive for both antibodies, anti-MBP and anti-myelin oligodendrocyte glycoprotein, had clinically definite MS within a mean of 7.5 months. To increase the sensitivity and specificity of MS diagnosis, a combination of antibodies, lymphocyte activation or cytokine production assessments along with an MRI, should be utilized. Autism Spectrum Disorder (ASD) presents with multiple biomolecular manifestations including neurological dysfunction. Compared to control subjects, ASD patients possess significantly higher levels of anti-brain antibodies, such as MBP, serotonin receptor, and brain endothelial cells or blood-brain barrier. Due to cross-reactivity to Streptococcal protein, MBP antibody is also found in PANDAS (pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection), its adult version ANDAS and Obsessive Compulsive Disorder (OCD). Indeed, the similarities of peptide sequences between Streptococcal proteins and MBP result in cross-reactivity. This autoimmune response triggers inflammation via myelin basic protein-specific T-cells, thus compromising the blood-brain barrier. A point of interest is that the administration of myelin basic protein artificially increases blood-brain barrier permeability and is under research as a possible treatment for rabies virus, which enters the brain to replicate itself. References: (https://www.cyrexlabs.com/Portals/0/Docs/SpecSheetPDFs/a5MBP.pdf) 1. Ashwood and Van de Water. Is autism an autoimmune disease? Autoimmunity Rev, 2004; 3:557-562. 2. Berger, et al. Antimyelin antibodies as a predictor of clinically definite Multiple Sclerosis after a first demyelinating event. N Engl Med, 2003; 349(2):139-145. 3. Gorgan, et al. Cross-reactivity of myelin basic protein-specific T cells with multiple microbial peptides: experimental autoimmune encephalomyelitis induction in TCR transgenic mice. J Immunol, 1999; 163:3764-3770. 4. Roy and Hooper. Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier. J Virol, 2007; 81(15):7993-7998. 5. Vojdani, et al. Antibodies to myelin basic protein, myelin oligodendrocytes peptides, a-B-crystallin, lymphocyte activation and cytokine production in patients with multiple sclerosis. J Internal Med, 2003; 254:363-374. 6. Vojdani. Obsessive compulsive disorder and differentiation between non-autoimmune OCD and the autoimmune version of the disease called PANDAS. Latitudes, 6(2):1-6. 7. Vojdani and Tarash. Cross-reaction between gliadin and different food and tissue antigens, Food Nutri Sci, 2013; 4:20-32. 8. Ebringer, et al. Acinetobacter immune responses in multiple sclerosis. Arch Neurol, 2005; 62:33-36. 9. Mameli, et al. Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides are cross recognized by anti-myelin basic protein antibodies in multiple sclerosis patients. J Neuroimmunol, 2014; 270(1-2):51-55. 10. Kharrazian and Vojdani. Correlation between antibodies to bisphenol A, its target enzyme protein disulfide isomerase and antibodies to neuron-specific antigens. J Appl Toxicol, 2017; 37:479-484.
Myelin is the protective sheath surrounding nerves
immature white blood cells
related to Cardiovascular disease and Myocardial infarction
When used in conjunction with other autoantibody tests (ANCA, PR3), may assist in evaluating suspected immune-mediated vasculitis, especially microscopic polyangiitis (MPA). May be useful when monitoring MPA disease and/or treatment response. -------------- Myeloperoxidase (MPO) enzyme is found in neutrophil primary granules and monocyte lysosomes. MPO catalyzes the conversion of hydrogen peroxide to hypochlorite and hypochlorous acid. MPO is encoded by a single gene that undergoes posttranslational modification to produce the active enzyme found in leukocytes. Autoantibodies to MPO (MPO antineutrophil cytoplasmic antibodies: ANCA) occur in several diseases and may be involved in the pathogenesis of vascular inflammation in patients with microscopic polyangiitis (MPA). Patients with MPA often develop MPO ANCA and may present with azotemia secondary to glomerulonephritis (pauci-immune necrotizing glomerulonephritis). MPO ANCA are not specific for MPA, and also may be detected in patients with systemic lupus erythematosus with or without lupus nephritis, Goodpasture syndrome and Churg-Strauss syndrome. Lupus nephritis and Goodpasture syndrome, as well as Wegener granulomatosis may present with azotemia and progressive renal failure. It is not possible to distinguish among these diseases on the basis of clinical signs and symptoms; autoantibody testing may be helpful.
Myocardial Peptides make up heart structure tissues
plays critical role in the early detection of muscle damage
A medium chain fatty acid (=MCFA)
A medium chain fatty acid (=MCFA)
A monounsaturated fatty acid
a metabolite of acrylonitrile